Revenio completed the acquisition of CenterVue for $67m.

Revenio, a Finland-based company primarily engaged in the health technology segment, completed the acquisition of CenterVue, a global supplier of ophthalmic devices, for $67m. "I am extremely pleased that the CenterVue acquisition has now been completed at a rapid pace and we can start the integration work as planned. The acquisition supports our goal of strengthening our position as the global market leader in devices for the diagnostics and monitoring of the eye, and glaucoma in particular. The well-known brands of both companies, the strong installed device base, and patent-protected technology enable us to offer the customers of both companies all modern products needed to diagnose glaucoma. CenterVue’s imaging products will also allow Revenio’s product portfolio to be expanded beyond glaucoma to rapidly increasing eye diseases. The personnel of both companies is extremely motivated and forward-looking, which I believe will significantly contribute to building common practices and corporate culture," Timo Hildén, Revenio CEO.